comparison between the effectiveness of furazolidone and clarithromycin on eradication of helicobacter pylori among patients with peptic ulcer

introduction: helicobacter pylori infections occur in about 50% of the world population and have a main role in the creation of peptic ulcer and its related cancer. we sought to evaluate the effectiveness of two treatment regimens on the eradication of helicobacter pylori and its complications among peptic ulcer patients. materials and methods: by a clinical trial, patients with peptic ulcer showing an infection compliance of more than 80%, confirmed by biopsy, were entered into the study and were randomly divided in two groups. group a was treated by medical regimen of amoxicilline, bismot, omeperasol and furazolidone (abof) and group b by medical regimen of amoxicilline, bismot, omeperasol and clarithromycin (aboc) for two weeks. in the next step, both groups were treated by only omeperasol for two weeks and finally, the infection rate of h. pylori was investigated by urea breath testing among both groups. results: among the 137 registered patients, 17 were unable to continue. the mean age of patients in group a, was 36.1 years and for group b, was 40.1 years. the rate of infection eradication in group a was 38.3% and in group b was 53.3% (p= 0.07). the most common symptoms among patients in group a were a bad taste mouth (80%) and headache (70%) and in the group b including headache (62%) and a bad taste mouth (60%) respectively. conclusion: abof regimen compared to aboc, showed a lower rate of infection eradication and also more complications for patients and the aboc was considered as the preferred regimen.